Ambrosia Biosciences
Develops orally delivered, small molecule-based therapies for obesity and other metabolic disorders
$100MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Develops orally delivered, small molecule-based therapies for obesity and other metabolic disorders
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases